<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01685658</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/PGC-01</org_study_id>
    <secondary_id>2015-002381-23</secondary_id>
    <nct_id>NCT01685658</nct_id>
  </id_info>
  <brief_title>Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations</brief_title>
  <acronym>PIVKIV</acronym>
  <official_title>Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study was to demonstrate the non-inferiority of intravenous&#xD;
      paracetamol relative to intravenous ketoprofen when treating renal colic in an emergency&#xD;
      ward. Efficacy is measured by the change in verbal numeric scale (vns) for pain at 30&#xD;
      minutes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:&#xD;
&#xD;
        -  To compare the efficacy (non-inferiority) of intravenous paracetamol and ketoprofen at&#xD;
           90 minutes (vns for pain).&#xD;
&#xD;
        -  To compare both arms in terms of other administered drugs (for pain).&#xD;
&#xD;
        -  To observe and compare side effects between the two arms: cutaneous manifestation,&#xD;
           edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness,&#xD;
           disturbance of consciousness, dyspnea, acute retention of urine.&#xD;
&#xD;
        -  To determine predictors for the use of intravenous morphine when treating renal colic.&#xD;
&#xD;
        -  To compare hospitalization rates between the two groups.&#xD;
&#xD;
        -  To compare patient satisfaction concerning care between the two groups (vns for&#xD;
           satisfaction)&#xD;
&#xD;
        -  To observe and compare changes towards complicated renal colic (obstructive&#xD;
           pyelonephritis, hyperalgesia, urinary tract rupture, need for surgical drainage, sepsis,&#xD;
           death)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    same study already published&#xD;
  </why_stopped>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vns for pain</measure>
    <time_frame>baseline to 30 minutes</time_frame>
    <description>Verbal numeric scale ranging from 0 to 10.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vns for pain</measure>
    <time_frame>baseline to 90 minutes</time_frame>
    <description>Verbal numeric scale ranging from 0 to 10.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) tramadol administered</measure>
    <time_frame>baseline (minute 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) tramadol administered</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) tramadol administered</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) tramadol administered</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) phloroglucinol administered</measure>
    <time_frame>baseline (minute 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) phloroglucinol administered</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) phloroglucinol administered</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) phloroglucinol administered</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Was morphine administered? yes/no</measure>
    <time_frame>baseline (minute 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) morphine administered</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) morphine administered</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) morphine administered</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Nefopam administered</measure>
    <time_frame>baseline (minute 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Nefopam administered</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Nefopam administered</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Nefopam administered</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Alfuzosine administered</measure>
    <time_frame>baseline (minute 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Alfuzosine administered</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Alfuzosine administered</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of (posology) Alfuzosine administered</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications</measure>
    <time_frame>baseline (minute 0)</time_frame>
    <description>cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications</measure>
    <time_frame>30 minutes</time_frame>
    <description>cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications</measure>
    <time_frame>90 minutes</time_frame>
    <description>cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications</measure>
    <time_frame>week 1</time_frame>
    <description>cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Was the patient hospitalized? yes/no</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Was the patient hospitalized? yes/no</measure>
    <time_frame>week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VNS for patient satisfaction concerning care</measure>
    <time_frame>week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution towards a complicated renal colic</measure>
    <time_frame>discharge from emergency ward (estimated max of 24 hours)</time_frame>
    <description>Qualitative variable with the following classes: obstructive pyelonephritis, hyperalgesia, urinary tract rupture, need for surgical drainage, sepsis, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution towards a complicated renal colic</measure>
    <time_frame>week 1</time_frame>
    <description>Qualitative variable with the following classes: obstructive pyelonephritis, hyperalgesia, urinary tract rupture, need for surgical drainage, sepsis, death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Renal Colic</condition>
  <condition>Acute Renal Colic</condition>
  <arm_group>
    <arm_group_label>Ketaprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.&#xD;
Intervention: intravenous ketaprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.&#xD;
Intervention: intravenous paracetamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ketoprofen</intervention_name>
    <description>Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)</description>
    <arm_group_label>Ketaprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous paracetamol</intervention_name>
    <description>Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)</description>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given his/her informed and signed consent&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
          -  The patient is available for a telephone interview at week 1&#xD;
&#xD;
          -  Patient consulting at the Nîmes University Hospital emergency ward with suspicion of&#xD;
             renal colic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another study&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the patient&#xD;
&#xD;
          -  The patient is pregnant, parturient, or breastfeeding&#xD;
&#xD;
          -  The patient has a contraindication for a treatment used in this study&#xD;
&#xD;
          -  The patient has an allergy to ketoprofen or paracetamol, a history of gastric or&#xD;
             intestinal ulcers, bleeding disorders, history of asthma triggered by taking&#xD;
             ketoprofen or substances with similar activity such as other NSAIDs or aspirin&#xD;
&#xD;
          -  The patient has a fever or is hemodynamically unstable, oligoanuria&#xD;
&#xD;
          -  The patient presents with an initial verbal numeric pain score of 10/10.&#xD;
&#xD;
          -  The patient has a history of aneurysm or aortic dissection, history of renal&#xD;
             transplantation, history of renal or hepatic insufficiency&#xD;
&#xD;
          -  The patient took paracetamol or ketoprofen 4 hours before emergency treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Géraud Claret, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH d'Alès</name>
      <address>
        <city>Alès</city>
        <zip>30103</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2012</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Renal Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

